Review anchor
Calcitonin gene-related peptide type 1 receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Calcitonin gene-related peptide type 1 receptor
CHEMBL3798
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Calcitonin gene-related peptide type 1 receptor as ChEMBL target CHEMBL3798, mapped to UniProt Q16602. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3798
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q16602
Calcitonin gene-related peptide type 1 receptor
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Calcitonin gene-related peptide type 1 receptor matters
Calcitonin gene-related peptide type 1 receptor is reviewed as Calcitonin gene-related peptide type 1 receptor (UniProt Q16602); Calcitonin gene-related peptide type 1 receptor shows approved-linked disease relevance led by migraine disorder. 5 more disease programs remain visible in the same review block.; 10 linked drugs keep this evidence frame grounded.; the current evidence base includes 5 approved drugs, 975 compounds, and 148 assays, with lead potency reaching pChEMBL 11.0.
Protein context
Calcitonin gene-related peptide type 1 receptor
Calcitonin gene-related peptide type 1 receptor Sequence length is 461 aa.
Review this target as Calcitonin gene-related peptide type 1 receptor, mapped to UniProt Q16602. Sequence length is 461 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q16602
Protein
Disease context
migraine disorder
Calcitonin gene-related peptide type 1 receptor shows approved-linked disease relevance led by migraine disorder. 5 more disease programs remain visible in the same review block. 10 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ATOGEPANT, BI-44370, ERENUMAB.
Start review with migraine disorder because it currently carries approved-linked support. Linked drugs include ATOGEPANT, BI-44370, ERENUMAB, MK3207. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
10 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 5 approved drugs, 975 compounds, and 148 assays for this target. The dominant activity type is IC50. CHEMBL207197 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL207197 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
5 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Calcitonin gene-related peptide type 1 receptor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q16602, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why migraine disorder is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
975
Total Compounds
148
Total Assays
5
Approved Drugs
IC50: 900.0, KI: 716.0, EC50: 14.0, KD: 10.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL207197
|
11.0 | Ki | Clinical |
|
|
No preferred name
CHEMBL454791
|
11.0 | Ki | — |
|
|
No preferred name
CHEMBL6015508
|
11.0 | IC50 | — |
|
|
No preferred name
CHEMBL5978732
|
11.0 | IC50 | — |
|
|
No preferred name
CHEMBL5865405
|
11.0 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ZAVEGEPANT
CHEMBL2397415
|
2023 |
|
|
ATOGEPANT
CHEMBL3991065
|
2021 |
|
|
RIMEGEPANT
CHEMBL2178422
|
2020 |
|
|
UBROGEPANT
CHEMBL2364638
|
2019 |
Source Header